← Eichor
Condition: Second Line Treatment Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Second Line Treatment

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Tr
Phase 2 · 1 location(s) · Dai, Guanghai · NCT07392346Ivonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell Carcinom
Phase 2 · 1 location(s) · Anhui Provincial Hospital · NCT07188103FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-S
Phase 2 · 13 location(s) · Oncolytics Biotech · NCT07446322Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
Phase 2 · 18 location(s) · VA Office of Research and Development · NCT04038502Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma
Phase 3 · 1 location(s) · Biotech Pharmaceutical Co., Ltd. · NCT05978050Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06446154Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Tre
Phase 3 · 16 location(s) · Genmab · NCT07225270Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer
Phase N/A · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06102772A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
Phase 1/Phase 2 · 1 location(s) · Akeso · NCT04982276Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy f
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07099274Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC
Phase 2 · 1 location(s) · Fudan University · NCT05229003Liposomal Irinotecan (II) Fractionated Dosing Combined With 5-FU/LV (FOLFIRInali-3) and Bevacizumab in Second-line Treat
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07047560A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.
NA · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT06371274Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer
Phase 1/Phase 2 · 1 location(s) · Fujian Cancer Hospital · NCT05019690A Phase IIII Study of AL8326 in Small Cell Lung Cancer
Phase 3 · 1 location(s) · Advenchen Laboratories Nanjing Ltd. · NCT06247605Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepati
Phase 2 · 7 location(s) · University Hospital, Montpellier · NCT03364530WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07330050Performance and Safety Evaluation of the FHK®-CK Knee Prosthesis
NA · 7 location(s) · FH ORTHO · NCT06124482Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial
Phase 2 · 1 location(s) · Shanghai Pudong Hospital · NCT07106034Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer
Phase 3 · 17 location(s) · Hutchmed · NCT06584032Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab
Phase 2 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT06540326RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure
Phase 1/Phase 2 · 1 location(s) · Tianjin Medical University Second Hospital · NCT06663007Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma
Phase 2 · 1 location(s) · West China Hospital · NCT06438822A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Out
Phase N/A · 17 location(s) · Novartis Pharmaceuticals · NCT07091019Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC
Phase 3 · 12 location(s) · Sun Yat-sen University · NCT05768503Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma
Phase 2 · 4 location(s) · UNICANCER · NCT06846346Radiopharmaceutical Treatment of Advanced Kidney Cancer
Phase 2 · 2 location(s) · European Organisation for Research and Treatment of Cancer - · NCT06783348Neoantigen-based Peptide Vaccine and Conventional Third-line Therapy for CRC Progressed After Second-line Treatment
NA · 2 location(s) · The First Affiliated Hospital of Nanchang University · NCT06751966High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Sec
Phase 2 · 1 location(s) · Changhai Hospital · NCT06394674Irinotecan Liposome in Combination With Capecitabine
NA · 1 location(s) · Junjie Hang · NCT06578052
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.